Bangladesh
· Delayed Price · Currency is BDT IBP Statistics
Total Valuation
Indo-Bangla Pharmaceuticals has a market cap or net worth of BDT 1.50 billion. The enterprise value is 1.52 billion.
| Market Cap | 1.50B |
| Enterprise Value | 1.52B |
Important Dates
The next estimated earnings date is Monday, October 28, 2024.
| Earnings Date | Oct 28, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Indo-Bangla Pharmaceuticals has 116.21 million shares outstanding. The number of shares has decreased by -5.98% in one year.
| Shares Outstanding | 116.21M |
| Shares Change (YoY) | -5.98% |
| Shares Change (QoQ) | +3.61% |
| Owned by Insiders (%) | 27.08% |
| Owned by Institutions (%) | 13.56% |
| Float | 84.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.80 |
| PB Ratio | 0.93 |
| P/FCF Ratio | 20.01 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 43.01, with an EV/FCF ratio of 20.33.
| EV / Earnings | -84.25 |
| EV / Sales | 7.20 |
| EV / EBITDA | 43.01 |
| EV / EBIT | n/a |
| EV / FCF | 20.33 |
Financial Position
The company has a current ratio of 4.67, with a Debt / Equity ratio of 2.18.
| Current Ratio | 4.67 |
| Quick Ratio | 2.07 |
| Debt / Equity | 2.18 |
| Debt / EBITDA | 0.99 |
| Debt / FCF | 0.47 |
| Interest Coverage | -0.57 |
Financial Efficiency
Return on equity (ROE) is -1.12% and return on invested capital (ROIC) is -0.09%.
| Return on Equity (ROE) | -1.12% |
| Return on Assets (ROA) | -0.08% |
| Return on Capital (ROIC) | -0.09% |
| Revenue Per Employee | 1.09M |
| Profits Per Employee | -93,217 |
| Employee Count | 194 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 0.94 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.71% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -24.71% |
| 50-Day Moving Average | 14.04 |
| 200-Day Moving Average | 15.92 |
| Relative Strength Index (RSI) | 36.82 |
| Average Volume (20 Days) | 237,834 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Indo-Bangla Pharmaceuticals had revenue of BDT 211.61 million and -18.08 million in losses. Loss per share was -0.16.
| Revenue | 211.61M |
| Gross Profit | 29.58M |
| Operating Income | -2.36M |
| Pretax Income | -6.22M |
| Net Income | -18.08M |
| EBITDA | 35.42M |
| EBIT | -2.36M |
| Loss Per Share | -0.16 |
Balance Sheet
The company has 10.48 million in cash and 35.01 million in debt, giving a net cash position of -24.53 million or -0.21 per share.
| Cash & Cash Equivalents | 10.48M |
| Total Debt | 35.01M |
| Net Cash | -24.53M |
| Net Cash Per Share | -0.21 |
| Equity (Book Value) | 1.61B |
| Book Value Per Share | 13.83 |
| Working Capital | 417.80M |
Cash Flow
In the last 12 months, operating cash flow was 88.41 million and capital expenditures -13.48 million, giving a free cash flow of 74.93 million.
| Operating Cash Flow | 88.41M |
| Capital Expenditures | -13.48M |
| Free Cash Flow | 74.93M |
| FCF Per Share | 0.64 |
Margins
Gross margin is 13.98%, with operating and profit margins of -1.12% and -8.55%.
| Gross Margin | 13.98% |
| Operating Margin | -1.12% |
| Pretax Margin | -2.94% |
| Profit Margin | -8.55% |
| EBITDA Margin | 16.74% |
| EBIT Margin | -1.12% |
| FCF Margin | 35.41% |
Dividends & Yields
Indo-Bangla Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 5.98% |
| Shareholder Yield | 5.98% |
| Earnings Yield | -1.26% |
| FCF Yield | 5.00% |
Stock Splits
The last stock split was on June 14, 2022. It was a forward split with a ratio of 1.03.
| Last Split Date | Jun 14, 2022 |
| Split Type | Forward |
| Split Ratio | 1.03 |